Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects

Florence F. Wagner, Joshua A. Bishop, Jennifer P. Gale, Xi Shi, Michelle Walk, Joshua Ketterman, Debasis Patnaik, Doug Barker, Deepika Walpita, Arthur J. Campbell, Shannon Nguyen, Michael Lewis, Linda Ross, Michel Weïwer, W. Frank An, Andrew R. Germain, Partha P. Nag, Shailesh Metkar, Taner Kaya, Sivaraman DandapaniDavid Olson, Anne Laure Barbe, Fanny Lazzaro, Joshua R. Sacher, Jaime H. Cheah, David Fei, Jose Perez, Benito Munoz, Michelle Palmer, Kimberly Stegmaier, Stuart L. Schreiber, Edward Scolnick, Yan Ling Zhang, Stephen J. Haggarty, Edward B. Holson, Jen Q. Pan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3) and indirectly by increasing GSK3's inhibitory serine phosphorylation. GSK3 comprises two highly similar paralogs, GSK3α and GSK3β, which are key regulatory kinases in the canonical Wnt pathway. GSK3 stands as a nodal target within this pathway and is an attractive therapeutic target for multiple indications. Despite being an active field of research for the past 20 years, many GSK3 inhibitors demonstrate either poor to moderate selectivity versus the broader human kinome or physicochemical properties unsuitable for use in in vitro systems or in vivo models. A nonconventional analysis of data from a GSK3β inhibitor high-throughput screening campaign, which excluded known GSK3 inhibitor chemotypes, led to the discovery of a novel pyrazolo-tetrahydroquinolinone scaffold with unparalleled kinome-wide selectivity for the GSK3 kinases. Taking advantage of an uncommon tridentate interaction with the hinge region of GSK3, we developed highly selective and potent GSK3 inhibitors, BRD1652 and BRD0209, which demonstrated in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. These new chemical probes open the way for exclusive analyses of the function of GSK3 kinases in multiple signaling pathways involved in many prevalent disorders.

Original languageEnglish (US)
Pages (from-to)1952-1963
Number of pages12
JournalACS Chemical Biology
Volume11
Issue number7
DOIs
StatePublished - Jul 15 2016
Externally publishedYes

Fingerprint

Glycogen Synthase Kinase 3
Phosphotransferases
Phosphorylation
Wnt Signaling Pathway
Hinges
Mood Disorders
Bipolar Disorder
Lithium
Scaffolds
Serine
Screening

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Wagner, F. F., Bishop, J. A., Gale, J. P., Shi, X., Walk, M., Ketterman, J., ... Pan, J. Q. (2016). Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chemical Biology, 11(7), 1952-1963. https://doi.org/10.1021/acschembio.6b00306

Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. / Wagner, Florence F.; Bishop, Joshua A.; Gale, Jennifer P.; Shi, Xi; Walk, Michelle; Ketterman, Joshua; Patnaik, Debasis; Barker, Doug; Walpita, Deepika; Campbell, Arthur J.; Nguyen, Shannon; Lewis, Michael; Ross, Linda; Weïwer, Michel; An, W. Frank; Germain, Andrew R.; Nag, Partha P.; Metkar, Shailesh; Kaya, Taner; Dandapani, Sivaraman; Olson, David; Barbe, Anne Laure; Lazzaro, Fanny; Sacher, Joshua R.; Cheah, Jaime H.; Fei, David; Perez, Jose; Munoz, Benito; Palmer, Michelle; Stegmaier, Kimberly; Schreiber, Stuart L.; Scolnick, Edward; Zhang, Yan Ling; Haggarty, Stephen J.; Holson, Edward B.; Pan, Jen Q.

In: ACS Chemical Biology, Vol. 11, No. 7, 15.07.2016, p. 1952-1963.

Research output: Contribution to journalArticle

Wagner, FF, Bishop, JA, Gale, JP, Shi, X, Walk, M, Ketterman, J, Patnaik, D, Barker, D, Walpita, D, Campbell, AJ, Nguyen, S, Lewis, M, Ross, L, Weïwer, M, An, WF, Germain, AR, Nag, PP, Metkar, S, Kaya, T, Dandapani, S, Olson, D, Barbe, AL, Lazzaro, F, Sacher, JR, Cheah, JH, Fei, D, Perez, J, Munoz, B, Palmer, M, Stegmaier, K, Schreiber, SL, Scolnick, E, Zhang, YL, Haggarty, SJ, Holson, EB & Pan, JQ 2016, 'Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects', ACS Chemical Biology, vol. 11, no. 7, pp. 1952-1963. https://doi.org/10.1021/acschembio.6b00306
Wagner, Florence F. ; Bishop, Joshua A. ; Gale, Jennifer P. ; Shi, Xi ; Walk, Michelle ; Ketterman, Joshua ; Patnaik, Debasis ; Barker, Doug ; Walpita, Deepika ; Campbell, Arthur J. ; Nguyen, Shannon ; Lewis, Michael ; Ross, Linda ; Weïwer, Michel ; An, W. Frank ; Germain, Andrew R. ; Nag, Partha P. ; Metkar, Shailesh ; Kaya, Taner ; Dandapani, Sivaraman ; Olson, David ; Barbe, Anne Laure ; Lazzaro, Fanny ; Sacher, Joshua R. ; Cheah, Jaime H. ; Fei, David ; Perez, Jose ; Munoz, Benito ; Palmer, Michelle ; Stegmaier, Kimberly ; Schreiber, Stuart L. ; Scolnick, Edward ; Zhang, Yan Ling ; Haggarty, Stephen J. ; Holson, Edward B. ; Pan, Jen Q. / Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. In: ACS Chemical Biology. 2016 ; Vol. 11, No. 7. pp. 1952-1963.
@article{763f5f0df6674918a5ca36f90fda6816,
title = "Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects",
abstract = "The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3) and indirectly by increasing GSK3's inhibitory serine phosphorylation. GSK3 comprises two highly similar paralogs, GSK3α and GSK3β, which are key regulatory kinases in the canonical Wnt pathway. GSK3 stands as a nodal target within this pathway and is an attractive therapeutic target for multiple indications. Despite being an active field of research for the past 20 years, many GSK3 inhibitors demonstrate either poor to moderate selectivity versus the broader human kinome or physicochemical properties unsuitable for use in in vitro systems or in vivo models. A nonconventional analysis of data from a GSK3β inhibitor high-throughput screening campaign, which excluded known GSK3 inhibitor chemotypes, led to the discovery of a novel pyrazolo-tetrahydroquinolinone scaffold with unparalleled kinome-wide selectivity for the GSK3 kinases. Taking advantage of an uncommon tridentate interaction with the hinge region of GSK3, we developed highly selective and potent GSK3 inhibitors, BRD1652 and BRD0209, which demonstrated in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. These new chemical probes open the way for exclusive analyses of the function of GSK3 kinases in multiple signaling pathways involved in many prevalent disorders.",
author = "Wagner, {Florence F.} and Bishop, {Joshua A.} and Gale, {Jennifer P.} and Xi Shi and Michelle Walk and Joshua Ketterman and Debasis Patnaik and Doug Barker and Deepika Walpita and Campbell, {Arthur J.} and Shannon Nguyen and Michael Lewis and Linda Ross and Michel We{\"i}wer and An, {W. Frank} and Germain, {Andrew R.} and Nag, {Partha P.} and Shailesh Metkar and Taner Kaya and Sivaraman Dandapani and David Olson and Barbe, {Anne Laure} and Fanny Lazzaro and Sacher, {Joshua R.} and Cheah, {Jaime H.} and David Fei and Jose Perez and Benito Munoz and Michelle Palmer and Kimberly Stegmaier and Schreiber, {Stuart L.} and Edward Scolnick and Zhang, {Yan Ling} and Haggarty, {Stephen J.} and Holson, {Edward B.} and Pan, {Jen Q.}",
year = "2016",
month = "7",
day = "15",
doi = "10.1021/acschembio.6b00306",
language = "English (US)",
volume = "11",
pages = "1952--1963",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects

AU - Wagner, Florence F.

AU - Bishop, Joshua A.

AU - Gale, Jennifer P.

AU - Shi, Xi

AU - Walk, Michelle

AU - Ketterman, Joshua

AU - Patnaik, Debasis

AU - Barker, Doug

AU - Walpita, Deepika

AU - Campbell, Arthur J.

AU - Nguyen, Shannon

AU - Lewis, Michael

AU - Ross, Linda

AU - Weïwer, Michel

AU - An, W. Frank

AU - Germain, Andrew R.

AU - Nag, Partha P.

AU - Metkar, Shailesh

AU - Kaya, Taner

AU - Dandapani, Sivaraman

AU - Olson, David

AU - Barbe, Anne Laure

AU - Lazzaro, Fanny

AU - Sacher, Joshua R.

AU - Cheah, Jaime H.

AU - Fei, David

AU - Perez, Jose

AU - Munoz, Benito

AU - Palmer, Michelle

AU - Stegmaier, Kimberly

AU - Schreiber, Stuart L.

AU - Scolnick, Edward

AU - Zhang, Yan Ling

AU - Haggarty, Stephen J.

AU - Holson, Edward B.

AU - Pan, Jen Q.

PY - 2016/7/15

Y1 - 2016/7/15

N2 - The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3) and indirectly by increasing GSK3's inhibitory serine phosphorylation. GSK3 comprises two highly similar paralogs, GSK3α and GSK3β, which are key regulatory kinases in the canonical Wnt pathway. GSK3 stands as a nodal target within this pathway and is an attractive therapeutic target for multiple indications. Despite being an active field of research for the past 20 years, many GSK3 inhibitors demonstrate either poor to moderate selectivity versus the broader human kinome or physicochemical properties unsuitable for use in in vitro systems or in vivo models. A nonconventional analysis of data from a GSK3β inhibitor high-throughput screening campaign, which excluded known GSK3 inhibitor chemotypes, led to the discovery of a novel pyrazolo-tetrahydroquinolinone scaffold with unparalleled kinome-wide selectivity for the GSK3 kinases. Taking advantage of an uncommon tridentate interaction with the hinge region of GSK3, we developed highly selective and potent GSK3 inhibitors, BRD1652 and BRD0209, which demonstrated in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. These new chemical probes open the way for exclusive analyses of the function of GSK3 kinases in multiple signaling pathways involved in many prevalent disorders.

AB - The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3) and indirectly by increasing GSK3's inhibitory serine phosphorylation. GSK3 comprises two highly similar paralogs, GSK3α and GSK3β, which are key regulatory kinases in the canonical Wnt pathway. GSK3 stands as a nodal target within this pathway and is an attractive therapeutic target for multiple indications. Despite being an active field of research for the past 20 years, many GSK3 inhibitors demonstrate either poor to moderate selectivity versus the broader human kinome or physicochemical properties unsuitable for use in in vitro systems or in vivo models. A nonconventional analysis of data from a GSK3β inhibitor high-throughput screening campaign, which excluded known GSK3 inhibitor chemotypes, led to the discovery of a novel pyrazolo-tetrahydroquinolinone scaffold with unparalleled kinome-wide selectivity for the GSK3 kinases. Taking advantage of an uncommon tridentate interaction with the hinge region of GSK3, we developed highly selective and potent GSK3 inhibitors, BRD1652 and BRD0209, which demonstrated in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. These new chemical probes open the way for exclusive analyses of the function of GSK3 kinases in multiple signaling pathways involved in many prevalent disorders.

UR - http://www.scopus.com/inward/record.url?scp=84978757601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978757601&partnerID=8YFLogxK

U2 - 10.1021/acschembio.6b00306

DO - 10.1021/acschembio.6b00306

M3 - Article

C2 - 27128528

AN - SCOPUS:84978757601

VL - 11

SP - 1952

EP - 1963

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 7

ER -